1. Home
  2. KLRS vs EXFY Comparison

KLRS vs EXFY Comparison

Compare KLRS & EXFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$5.55

Market Cap

144.9M

Sector

Health Care

ML Signal

HOLD

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$1.05

Market Cap

132.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLRS
EXFY
Founded
2019
2008
Country
United States
United States
Employees
20
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
144.9M
132.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
KLRS
EXFY
Price
$5.55
$1.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$19.00
$4.50
AVG Volume (30 Days)
74.4K
590.0K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$142,101,000.00
Revenue This Year
N/A
$0.42
Revenue Next Year
N/A
$0.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.06
52 Week Low
$2.14
$0.69
52 Week High
$11.88
$3.06

Technical Indicators

Market Signals
Indicator
KLRS
EXFY
Relative Strength Index (RSI) 36.83 66.71
Support Level $5.26 $0.77
Resistance Level $7.18 $1.54
Average True Range (ATR) 0.47 0.06
MACD 0.04 0.03
Stochastic Oscillator 11.90 100.00

Price Performance

Historical Comparison
KLRS
EXFY

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.

Share on Social Networks: